PeptideScouterPeptideScouterIndex

Semaglutide in Children Ages 6 to 11: STEP Young Results

· Updated Thursday, November 19, 2026 · News

On November 16, 2026, The New England Journal of Medicine published the full results of STEP Young, a Phase 3 trial of semaglutide, the active ingredient in Wegovy, in children 6 to under 12 years old with obesity. Novo Nordisk sponsored the trial, reported headline results in September 2026 and presented the full data, including the 104-week results, at ObesityWeek 2026 in Washington, D.C. At 68 weeks, body-mass index (BMI) fell 13.5% with semaglutide and rose 2.7% with placebo, counting every child whether or not they stayed on treatment.

Wegovy is approved in the United States for weight management from age 12. Novo states that semaglutide is not approved in the United States for children under 12.

The trial

STEP Young was double-blind and placebo-controlled, with sites in ten countries, the United States among them. It randomly assigned 167 children in a 2:1 ratio, 112 to semaglutide and 55 to placebo, for 104 weeks of treatment followed by a 7-week washout. Both groups received counseling on a reduced-calorie diet and increased physical activity. More than 85% of the children had class II or III obesity at the start.

The primary endpoint was the percent change in BMI at week 68, and the confirmatory secondary endpoint was a move to a lower BMI category. Trials in children measure BMI rather than body weight because children are still growing. Obesity in a child is a BMI at or above the 95th percentile for age and sex on the growth charts of the Centers for Disease Control and Prevention (CDC), and classes II and III start at 120% and 140% of that threshold.

Results at 68 weeks

Novo reports two analyses. The treatment regimen estimand counts every child, whether or not they stayed on treatment, and is the primary analysis. The efficacy estimand assumes every child stayed on treatment.

Results at 104 weeks

Counting every child, BMI was 9.4% below baseline with semaglutide and 8.4% above it with placebo at week 104, a difference of 17.8 percentage points. Under the efficacy estimand the figures were -14.0% and +5.7%. The mean reduction on semaglutide was smaller than at week 68, while the gap with placebo held. In the semaglutide group, 33.3% of children were below the obesity threshold at week 104, against 2.4% on placebo. Novo notes that the week-104 analyses were not adjusted for multiple comparisons, so they cannot support firm conclusions.

Safety

Adverse events occurred in 96% of children on semaglutide and 93% on placebo. Gastrointestinal events were the most common, occurred more often with semaglutide and led one child on semaglutide to stop treatment. Novo says the safety profile matched earlier semaglutide trials in children and adults, and that it identified no safety concerns for growth or pubertal development.

Earlier GLP-1 trials in children

Novo has run earlier trials of glucagon-like peptide-1 (GLP-1) receptor agonists in young people with obesity, and two of them, both published in The New England Journal of Medicine, are the nearest comparisons. Eli Lilly published an adolescent trial of tirzepatide a day before STEP Young.

The four trials enrolled different age groups, ran for different lengths and tested different drugs, so their results cannot rank the drugs against each other.

What comes next

Novo's November 16 release does not say whether or when it will ask the Food and Drug Administration (FDA) to extend Wegovy's label to children under 12. ClinicalTrials.gov lists the study as active but not recruiting, with completion estimated for December 2026.

The results apply to Novo's product as tested in the trial. They do not extend to research-grade semaglutide, a separate material sold for laboratory research and not approved for any use in people.

Sources

Sources checked November 18, 2026.

PeptideScouter indexes vendor prices for research chemicals sold for laboratory use only, not for human consumption. Nothing here is medical, legal, or investment advice. We earn affiliate commissions on some outbound vendor links - see our disclosure.